A broad-spectrum antimicrobial agent, a derivative of fluoroquinolone, inhibits bacterial DNA-gyrase, Breaks the synthesis of DNA, growth and division of bacteria; Causes pronounced morphological changes and rapid death of the bacterial cell.
Indications for use
Acts bactericidal against gram-negative organisms in the period of rest and division, on gram-positive microorganisms - only in the period of division. Low toxicity for macroorganism cells is explained by the absence of DNA-gyrase in themAgainst the background of taking ciprofloxacin, there is no parallel development of resistance to other antibiotics that do not belong to the group of inhibitors of gyrase, which makes it highly effective against bacteria that are resistant, for example, to aminoglycosides, penicillins, cephalosporins, tetracyclines and many other antibiotics.
- Infections of the kidneys and urinary tract (acute or chronic pyelonephritis, cystitis, complicated or recurrent urinary tract infections, prostatitis, epididymitis);
- respiratory tract infections (pneumonia, bronchopneumonia, pleurisy, abscess of the lungs, infected bronchiectasis, exacerbation of chronic bronchitis);
- skin and soft tissue infections (infected ulcers, wound infections, abscesses, cellulitis, infected burns);
- infections of the gastrointestinal tract (cholangitis, cholecystitis, gall bladder empyema, typhoid fever, bacterial diarrhea, etc.);
- infection of the abdominal cavity (peritonitis, intra-abdominal abscess);
- infection of the ENT organs (inflammation of the paranasal sinus);
- eye infections;
- infections of the musculoskeletal system;
- infection of the genitals;
- infections of the pelvic organs;
- prevention and treatment of infections in patients with decreased immunity (with immunosuppressant therapy).